

[PLOS.ORG](#)

[PUBLICATIONS](#)

Search PLOS Blogs



Diverse perspectives on science and medicine

[STAFF BLOGS](#) ▾

[BLOGS BY TOPIC](#) ▾

[ABOUT PLOS BLOGS](#)

[CONTACT](#)



About This Blog

Search This Blog



[< Previous](#)

[Next >](#)



Talking drug prices, Pt 6: Openness vs. secrecy in drug development By Mat Todd

Posted October 22, 2015 by [Victoria Costello](#) in [ethics](#), [Global health](#), [Open Access](#), [Research Ethics](#), [Your Say](#)

◀ 45

[0000-0002-8715-2896](#)

Welcome to the sixth and final post in a PLOS BLOGS series, Talking about Drug Prices & Access to Medicines. To borrow a phrase from one of our bloggers, “Rage and public outcries are not a rational way to manage high drug prices.” We agree, while also acknowledging that the recent public and media uproar over the 5000% price hike and subsequent “roll back” of a 40 year old medicine by Turing Pharmaceuticals may have opened a useful window on larger issues, including misaligned incentives around drug R&D efforts and the related unavailability of necessary medicines to people around the world.

Each post presents a different point of view on these issues, and we encourage you to read all six parts — with titles and authors listed at the bottom of this post. For the series, PLOS BLOGS Network benefited from the involvement of PLOS Medicine Chief Editor, Larry Peiperl. — Victoria Costello, PLOS BLOGS Network



In drug development, openness can compete with secrecy, given

[< Previous](#)[Next >](#)**Victoria Costello**

As PLOS Senior Social Media & Community Editor, Victoria Costello oversees the organization's social media efforts and manages the PLOS BLOGS Network. Prior to joining PLOS in 2012, Costello worked as an science journalist and author in the areas of psychology and neuroscience. orcid.org/0000-0002-8715-2896

2 comments

Pingback: Talking drug prices #6: Openness vs. secrecy in drug development | Don't trade our lives away

Pingback: Talking drug prices, Pt 6: Openness vs. secrecy in drug development By Mat Todd - PLOS Blogs Network

Leave a Comment

Comment

Name*

Email*

Website

ORCID

Add your ORCID here. (e.g. 0000-0002-7299-680X)

Post

Sign up for PLOS Updates

Email Address (required)

Sign Up

Featured Zika Posts



Popular Posts



Repost: The Top Ten Ways to Tell that a...
March 22, 2017



Opinion: Who should lead WHO (Pt 1 of...
April 5, 2017



Researcher 'First Person': Why...
February 14, 2017

Recent Posts



Rex Tillerson shouldn't cut global.
July 20, 2017



Helping countries transition from...
July 10, 2017



Repost: The Top Ten Ways to Tell that a...
March 22, 2017



[Home](#)

[About](#)

[Guidelines](#)

[Contact](#)



[LOGIN](#)

PUBLICATIONS

[PLOS Biology](#)

[PLOS Medicine](#)

[PLOS
Computational
Biology](#)

[PLOS Currents](#)

[PLOS Genetics](#)

[PLOS Pathogens](#)

[PLOS ONE](#)

[PLOS Neglected
Tropical
Diseases](#)

OPEN FOR DISCOVERY

[plos.org](#)

[PLOS Collections](#)

[PLOS Channels](#)

[Careers](#)

[Advertise](#)

[Privacy Policy](#)

[Terms of Use](#)